Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. METHODS: Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected. RESULTS: The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokinetic parameters were similar whether the insulin degludec pharmacokinetic assessment period included hemodialysis or not, and total exposure was comparable to subjects with normal renal function. Simulated mean steady-state pharmacokinetic profiles were comparable between groups. CONCLUSION: This study indicated dose adjustments due to impaired renal function should not be required for insulin degludec.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Simulated mean SS profiles demonstrated an even distribution of exposure to IDeg across a 24-h dosing interval, regardless of renal or hepatic function status, indicating that the pharmacokinetic properties observed in patients with normal renal or hepatic function are preserved in patients with impaired renal or hepatic function [27, 28].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Serum, urine and dialysate (where relevant) concentrations of IDeg were measured using a specific sandwich enzyme-linked immunosorbent assay [21, 22, 27, 28].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Haemodialysis did not affect the pharmacokinetic profile of IDeg in subjects with end-stage renal disease (ESRD) undergoing haemodialysis.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“This finding is further corroborated in a SD, open-label, parallel-group trial that demonstrated the pharmacokinetic characteristics of IDeg are preserved in adult subjects with different degrees of renal impairment [28].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Total exposure and C max of IDeg, as well as the apparent total clearance from plasma after SC administration (CL/F) of IDeg were comparable in subjects with normal and varying degrees of impaired renal function (Table 3).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036 · cited 1×
“Impaired renal function is an increasingly common longterm complication of diabetes mellitus [1, 2].”
BackgroundDesign of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 1×
“Upon subcutaneous injection, insulin degludec forms long chains of multi-hexamers, resulting in a soluble depot in the subcutaneous tissue from which insulin degludec monomers gradually separate [21, 22].”
BackgroundFrequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423 · cited 2×
“As exogenous insulin is primarily cleared via renal metabolism [1, 7–9], impaired renal function in patients with diabetes can result in decreased clearance of insulin”
BackgroundHeller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“lowering effect [23], with a four-times lower within-subject variability in glucose-lowering effect [area under the curve (AUC) values] than insulin glargine [24].”
BackgroundSelf-citationRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 1×
“These properties of insulin degludec lead to a decreased risk of hypoglycemia compared with insulin glargine [24–28].”
Background
Research works printed but not linked: 3
- Lynes W Tyler JF Lawrence A Renal impairment does not affect insulin aspart pharmacokinetics in type 1 diabetes Diabetes 2001 50 suppl 2 A441 A442
- Jacobsen LV Popescu G Plum A Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment Diabetologia 2002 45 suppl 1 A259
- Kurtzhals P Heise T Strauss HM Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec Diabetologia 2011 54 Suppl 1 S426
Cited by
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
“trial that demonstrated the pharmacokinetic characteristics of IDeg are preserved in adult subjects with different degrees of renal impairment [28].”
BackgroundMethodResultInfluentialSelf-citationInteractions between kidney disease and diabetes: dangerous liaisons
Pecoits-Filho, R., Abensur, H., Betônico, C. C. R., Machado, A. D., Parente, E. B., Queiroz, M., Salles, J. E. N., Titan, S., & Vencio, S. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 171
“Thus, degludec insulin does not require dose adjustments due to the loss of kidney function [138].”
BackgroundDerivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 153
Cyclic Peptide Screening Methods for Preclinical Drug Discovery
Li, X., Craven, T. W., & Levine, P. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01077 · Cited by 101
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 93
“However, increasing the hydrodynamic size of the insulin, such as insulin peglispro (103), or binding acylated insulins to HSA, such as IDeg (104), can eliminate the need for insulin dose adjustments in diabetes patients with CKD.”
Davies, M., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 75
“Likewise, in one clinical study, renal impairment did not have a significant effect on maximum concentration (C max ), apparent clearance, or AUC 0–120 h of single-dose degludec.(30,54) The glucodynamic response to insulin lispro is not affected by renal impairment.”
Clinical use of insulin degludec
Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73
“the elderly and those with hepatic or renal impairment (including those with end-stage renal disease) [30–32].”
BackgroundBetônico, C. D. C. R., Titan, S., Corrêa‐Giannella, M. L., Nery, M., & Queiroz, M. S. (2016) · Clinics · doi:10.6061/clinics/2016(01)08 · Cited by 88
“A new-generation basal insulin with an ultra-long duration of action, insulin degludec, was approved to be commercialized, but there has been just one study in patients with different GFRs (54).”
BackgroundMethodConcentrated insulins: the new basal insulins
Davis, S. N., Lamos, E. M., & Younk, L. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s99855 · Cited by 61
“73 m(2)), hemodialysis, or liver dysfunction (Child–Pugh grade A–C) is not required.(19,20) Exposure and clearance of degludec U100 were similar to individuals with normal renal and hepatic function, although intensification of glucose monitoring and individualized dosing for those with renal or hepatic impairment is…”
Pathophysiology and Management of Hypoglycemiain End-Stage Renal Disease Patients: A Review
Gianchandani, R. Y., Neupane, S., Iyengar, J. J., & Heung, M. (2016) · Endocrine Practice · doi:10.4158/ep161471.ra · Cited by 54
Haahr, H. L., Fita, E. G., & Heise, T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0455-7 · Cited by 49
“In addition, total exposure, maximum concentration and clearance of IDeg were similar in patients with ESRD compared with subjects with normal renal function, and haemodialysis had no impact on the pharmacokinetic profile of IDeg [61].”
BackgroundSelf-citationInsulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
Kupčová, V., Arold, G., Roepstorff, C., Højbjerre, M., Klim, S., & Haahr, H. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-013-0154-1 · Cited by 40
“varying degrees of impaired renal function on the pharmacokinetics of insulin degludec found that pharmacokinetic properties were also preserved in subjects with renal impairment [24].”
BackgroundSelf-citationDegludec: the new ultra-long insulin analogue
Tambascia, M. A., & Eliaschewitz, F. G. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0037-0 · Cited by 41
“Again, no differences were observed in the AUC120-h, in Cmax and in CL/F for individuals with impaired versus normal renal function [22].”
BackgroundUse of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 39
“73 m(2).(95,96) Total daily insulin dose requirements typically decrease by approximately 25% when estimated GFR falls below 60 ml/min per 1.”
BackgroundRoussel, R., Lorraine, J., Rodríguez, Á., & Salaun-Martin, C. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0261-x · Cited by 38
“For the basal insulin analogs, PK studies involving insulin detemir and insulin degludec showed no differences in PK properties between subjects with normal renal function and those with renal impairment [109, 112, 171, 172].”
BackgroundHaluzík, M., CHENG, A. Y. Y., Müller‐Wieland, D., Westerbacka, J., Bosnyák, Z., Lauand, F., Melas‐Melt, L., Karalliedde, J. J., Rosenstock, J., & Bolli, G. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14043 · Cited by 32
Consensus statement on insulin therapy in chronic kidney disease
Rajput, R., Sinha, B., Majumdar, S., Shunmugavelu, M., & Bajaj, S. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.032 · Cited by 33
Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis
Iyengar, R., Franzese, J., & Gianchandani, R. Y. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1044-y · Cited by 31
Blaine, E., Tumlinson, R., Colvin, M., HAYNES, T. G., & Whitley, H. P. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2659 · Cited by 26
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 31
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
Miccoli, R., Dardano, A., Bianchi, C., & Prato, S. D. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40097 · Cited by 19
Haahr, H. L., Cieslarová, B., Hingst, J. R., Jiang, S., Kristensen, N. R., Kupčová, V., Nørgreen, L., Wagner, F.-D., & Ignatenko, S. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01375-2 · Cited by 18
“In contrast, the pharmacokinetics of insulin aspart, insulin detemir and insulin degludec appear not to be affected by renal impairment [9–11].”
BackgroundSelf-citationCurrent therapeutic approaches in the management of hyperglycemia in chronic renal disease
Garla, V. V., Yanes-Cardozo, L. L., & Lien, L. F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9416-1 · Cited by 19
Clinical use of the co-formulation of insulin degludec and insulin aspart
Kumar, A., Awata, T., Bain, S. C., Ceriello, A., Fulcher, G. R., Unnikrishnan, A., Arechavaleta, R., González-Gálvez, G., Hirose, T., Home, P., et al. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12821 · Cited by 17
Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease
Escott, G. M., da Silveira, L. G., Cancelier, V. D. A., Dall’Agnol, A., & Silveiro, S. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107774 · Cited by 17
de Sá, J. R., Rangel, É. B., Canani, L. H. S., Bauer, A. C., Escott, G. M., Zelmanovitz, T., Bertoluci, M. C., & Silveiro, S. P. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00843-8 · Cited by 23
“Regarding basal insulins, glargine (U100 and U300), degludec, and detemir are stable and effective, but there are few studies in this population (patients with DKD), indicating that they are associated with a reduction in hypoglycemia, especially degludec when compared to detemir and glargine U100 [77, 78].”
BackgroundInfluentialGlastras, S. J., Cohen, N. D., Dover, T., Kilov, G., MacIsaac, R. J., McGill, M. J., & Fulcher, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041091 · Cited by 17
“The pharmacokinetic profile of insulin degludec was found to be similar in patients with renal or hepatic impairment and individuals without impairment [63,64].”
BackgroundRSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 17
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
Kerlan, V., Thuillier, P., & Alavi, Z. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54953 · Cited by 15
“pharmacokinetic profile of IDeg in the presence of chronic renal insufficiency and hepatic impairment and confirmed no changes in these subgroups of patients when compared with healthy volunteers.(11,12) Given the particularly stable plasma concentrations of IDeg, two main hypotheses should be be evaluated: first, whe…”
ResultUltra-long-acting insulins: A review of efficacy, safety, and implications for practice
Davis, C. S., Fleming, J. W., Malinowski, S. S., Brown, M. A., & Fleming, L. W. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000076 · Cited by 17
de Sá, J. R., Rangel², É. B., Bauer, A. C., Betônico, C. D. C. R., Zelmanovitz, T., Moura, A. F. D. S., Silveiro, S. P., Canani, L. H. S., Lauria, M. W., Lamounier, R. N., et al. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-18 · Cited by 19
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Zhai, J., Li, L., Dong, L., Dong, K., Xiang, S., Gui, L., Zhang, J., Song, H., & Ge, Z. (2020) · Biomedical Chromatography · doi:10.1002/bmc.4921 · Cited by 10
Ghosal, S., Sinha, B., & Gangopadhyay, K. K. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.013 · Cited by 9
Ikushima, I., Kaku, K., Hirao, K., Bardtrum, L., & Haahr, H. L. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12399 · Cited by 9
Self-citationPreumont, V., & Buysschaert, M. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.04.007 · Cited by 8
Uchida, J., Oikawa, Y., Katsuki, T., Takeda, H., Shimada, A., & Kawai, T. (2017) · Diabetic Medicine · doi:10.1111/dme.13557 · Cited by 9
D’Souza, S., & Kruger, D. F. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00920-z · Cited by 7
Basal insulin analogues in people with diabetes and chronic kidney disease
Jiménez, D. L., Miramontes‐González, J. P., Márquez‐López, L., Astudillo‐Martín, F., Beltrán, L. M., Obregón, F. M., & Martín, J. E. (2021) · Diabetic Medicine · doi:10.1111/dme.14679 · Cited by 7
“Only 13% (44) of the participants had an eGFR of 30– 59 ml/ min and 3% (10) an eGFR of 15– 29 ml/min.”
BackgroundDiabetes and Glucose Management in People on Hemodialysis
Agarwal, S., Mader, J. K., Arevalo, G., Avula, S., Chavez, E., Sloan, L. A., & Galindo, R. J. (2025) · Diabetes Spectrum · doi:10.2337/dsi24-0015 · Cited by 7
Evaluación clínica y tratamiento de la diabetes en pacientes con enfermedad renal crónica
Carretero‐Gómez, J., & Arévalo‐Lorido, J. C. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.03.016 · Cited by 14
Clinical assessment and treatment of diabetes in patients with chronic kidney disease
Carretero‐Gómez, J., & Arévalo‐Lorido, J. C. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2018.03.010 · Cited by 8
Kaku, K., & Eid, M. A. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12348 · Cited by 6
Review of Clinical Profile of IDegAsp.
Unnikrishnan, A. G., Singh, A. K., Modi, K. D., Saboo, B., Garcha, S. C., & Rao, P. V. (2015) · PubMed · Cited by 6
Sloan, L. A., CHENG, A. Y. Y., Escalada, J., Haluzík, M., & Mauricio, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15425 · Cited by 4
Special considerations for the treatment of chronic kidney disease in the elderly
Corsonello, A., Fusco, S., Bustacchini, S., Chiatti, C., Moresi, R., Bonfigli, A. R., Stefano, G. D., & Lattanzio, F. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1155448 · Cited by 7
“different degrees of kidney dysfunction [61], thus suggesting that dose adjustments in patients with mild to severe renal”
BackgroundRenal safety of newer medications
Puttanna, A., & Varadhan, L. (2016) · Practical Diabetes · doi:10.1002/pdi.2013 · Cited by 3
Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes
Sanyal, D., Chaudhuri, S. R., & Majumder, A. (2020) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2020.100071 · Cited by 5
Oishi, A., Makita, N., Manaka, K., Mitani, K., Tomita, H., & Iiri, T. (2015) · Diabetology International · doi:10.1007/s13340-015-0220-4 · Cited by 2
In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec
WANGNOO, S. K., Baruah, M. P., Lodha, S., Sanyal, D., Goyal, R., Sooragonda, B. G., Chandrasekaran, S., & Kumar, G. V. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01707-w · Cited by 2
“IDeg is effective and well tolerated in patients with hepatic or renal impairment, as its PK properties are preserved in these populations, allowing safe use without extensive dose adjustments [67, 68].”
Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients
Bajwa, S. S., Kalra, S., & Bajwa, S. (2015) · Medical Journal of Dr D Y Patil University · doi:10.4103/0975-2870.164970 · Cited by 1
Degludec: a long-duration insulin
Alexanderson-Rosas, E. G., Llamas-Moreno, J. F., Castro-Martínez, M. G., Frenk-Barón, P., Romo-Pérez, O. A., & Mena-Madrazo, J. A. (2015) · Medicina Interna de México · Cited by 2
Expanded Basal Insulin Options for Type 2 Diabetes Mellitus
Olin, J. L., & Harris, K. B. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.07.011 · Cited by 2
Takahashi, N., Tsujimoto, T., Inoue, K., Kishimoto, M., & Kajio, H. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12500 · Cited by 1
Inpatient Management of Patients with Diabetes and Kidney Disease
Patel, E., Kim, S. H., & Gianchandani, R. Y. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_23 · Cited by 2
Modern basal insulins: an ongoing story or the start of a new era?
Dedov, I. I. (2015) · Diabetes Mellitus · doi:10.14341/dm7693 · Cited by 2
Solini, A., & Castellino, P. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_8-2 · Cited by 1
Efficacy, safety and clinical use of newer basal insulins analogs
Neto, A. M., & Ferrari, M. T. M. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00178 · Cited by 2
Betônico, C. D. C. R. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-05042017-153224 · Cited by 1
Glucose variability in maintenance hemodialysis patients with type 2 diabetes
Fačkovcová, L., Barlovič, D. P., & Brož, J. (2023) · Hemodialysis International · doi:10.1111/hdi.13089 · Cited by 1
“For example, the pharmacokinetics of insulin detemir or degludec is not affected by renal impairment, whereas this is not true for insulin glargine or human insulin products.(3) Also, an analysis of the correlation between the daily amount of insulin and glucose concentration changes might support the author’s explana…”
BackgroundRecent advances with insulin degludec for the treatment of Type 2 diabetes
Stokes, V. J., & Gough, S. C. L. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.917045
“In patients undergoing hemodialysis, the total exposure was comparable between the groups and the PK parameters were similar, whether or not the subject had hemodialysis during the assessment period [51].”
ResultMedina, A. G. M., Olivares, C., Salinas, C., Rosselli, C., Barón, R. A., Ocampo, D., Tovar, A. P., Rincón, O., Villegas, I., & Fortich, Á. (2018) · Alad · doi:10.24875/alad.17000236
Mácsai, E. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.15
Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes
Hahr, A. J., & Molitch, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_23
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
Umpierrez, G. E. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42964-7
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
Garber, A. J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42963-5
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
Solini, A., & Castellino, P. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_8
Solini, A., & Castellino, P. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_8 · Cited by 1
Solini, A., & Castellino, P. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_8-1
Gilbert, J. D., McFarlane, P., Kim, J., Jin, S., Senior, P. A., Gilbert, J. D., BAJAJ, H. S., Jin, S., Kim, J., BAJAJ, H. S., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.01.006
Second Generation Basal Insulin, Degludec, in the Management of Diabetes; Consensus Report
Alsifri, S. N., Alshahrani, A., Aldawish, M., Alyahia, K., Alharbi, B., Moloy, H., Alrumiah, A., Evans, M., Bokhari, S., & Issak, E. R. (2023) · Clinical Reviews & Cases · doi:10.33425/2689-1069.1049 · Cited by 1
Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach: Chronic Kidney Disease
Corsonello, A., Rocca, A., Russo, C. L., & Soraci, L. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_28 · Cited by 2
MESA 1: NUEVOS MEDICAMENTOS EN DIABETES MELLITUS TIPO 1
Litwak, L., Martín, C. G., Garrido, N., Koleff, C. K., Canda, M. E., Burgos, M. A., Bertollo, N., Scaliti, M. G., Blanco, M. A., Calvo, M. L., et al. (2015) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v49i3.633
“En éstos, no requeriría ajuste de dosis 20 .”
BackgroundBindingDB Entry 50015977: Cyclic Peptide Screening Methods for Preclinical Drug Discovery.
BindingDB (2023) · UC San Diego · doi:10.7270/q24q7zzw
Metadata
- Authors
- Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H.
- Affiliations
- Szent Imre Egyetemi Oktatókórház (HU)
- PRA Health Sciences (US)
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Kiss, István
- Venue
- Clinical Pharmacokinetics
- Published
- 2013-10-26
- Volume
- 53
- Issue
- 2
- Pages
- 175-183
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC3899495
- OpenAlex
- W2037694686
- Semantic Scholar
- 505604e3a2fdcc5149ff748c3a9db7ec89d57693
- Cited by
- 75
- References
- 27
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 1 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 16 · 2015: 12 · 2014: 4 · 2013: 1
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Amgen
- Sanofi
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- insulin degludec, pharmacokinetics, renal dysfunction, end-stage renal disease, hemodialysis, basal insulin, ultra-long-acting insulin, dose adjustment, drug clearance, urinary excretion
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Renal Dialysis, Humans, Hypoglycemic Agents, Kidney, Male, Middle Aged, Dialysis Solutions, Insulin, Long-Acting, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.